News

ICMR approves TB machines for Covid-19 testing

Maitri Porecha New Delhi | Updated on April 04, 2020 Published on April 04, 2020

ICMR will procure seven lakh US FDA-EUA/CE-IVD/ICMR-NIV Pune-approved RNA extraction kits. Representative image   -  Bloomberg

Diagnostic machines used to test drug-resistant tuberculosis (TB) have now been approved by Indian Council of Medical Research (ICMR) for conducting Covid-19 tests.

“ICMR has recommended use of Truenat beta CoV test on Truelab workstation validated by ICMR as a screening test. Also, use of US-FDA approved closed real time Polymerase Chain Reaction (RT-PCR) systems like GeneXpert and Roche Cobas - 6800/800 have been approved under emergency use,” ICMR has stated in its guidance.

A top executive from Molbio diagnostics which manufactures Truenat told Businessline that the company already has over 800 Truenat machines in place across India primarily for use in detecting drug-resistant TB, of which close to 400 were in government set-ups. Out of which 257 are in Andhra Pradesh alone, at district and sub-district level.

Truenat

While GeneXpert is a cartridge-based technology, Truenat is smaller, battery operated, requires minimal training and is usable even in smaller settings such as the Primary Health Centre. It uses a chip-based technology and takes just up to 60 minutes for a test, screening or confirmatory.

“While the testing platform that was being used for TB remains the same, we need to equip these centres with Covid-19 testing kits. In a four-way Truenat machine, one can run up to 32 to 48 samples of multiple diseases - COVID19, HIV and TB. We just have to feed in the respective test profile in the machine and it can process multiple diseases at one time,” the executive said.

Of the 800 machines, 150 to 200 machines are two-way and can handle 16 to 24 samples, there are about 50 four-way machines and rest of them are single-way machines, which can process 8 to 12 samples at a time. The cost of a test on Truenat will be ₹1,000-₹1,500, the executive said. This is a fifth of what it costs today. While Molbio wants to expand its manufacturing capacity and place more machines on ground, the executive said that they were awaiting for the government directives on the number of machines and tests needed in each state.

“We are in close touch with states to scale up our manufacturing capacities as also for supplying testing kits. Once the throat and nasal swab sample is safely collected by trained technicians wearing personal protective equipment, it is rendered non-infectious in the machine and results are obtained between 30 and 60 minutes,” the executive said.

One big concern is India’s inability to manufacture local kits. “We are mostly dependent on imports from the US or other countries for acquiring kits,” said the executive.

Published on April 04, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
medical research
coronavirus
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.